All News
What does avacopan mean for sustained remission in AAV?
New post-hoc from ADVOCATE - keeping in mind the avacopan was instead of steroids. Impressive numbers, so increasingly the questions will be about strategy and cost?
#EULAR2022 @RheumNow https://t.co/B4y8jZiHf5
David Liew drdavidliew ( View Tweet)
🚨 Study on MTX and male fertility
Analysis of semen parameters in
🙋🏼♂️HC
🙋🏼♂️RA, PsA and PsO MTX naive
🙋🏼♂️Post MTX
Reassuring data as NO significant effect of MTX was observed on several semen parameters.
#EULAR2022 @RheumNow
OP0131 https://t.co/Fq32lzAMAx
Aurelie Najm AurelieRheumo ( View Tweet)
#Belimumab safety in pregnancy
EudraVigilance database retrospect study 47 preg: BEL stopped 1st trimester (group A) vs. cont'd (group B)
- no diff in fetal death
- more preterm birth/low birth weight, congenital malform'n in group A (not stat sig) #EULAR2022 @rheumnow POS0705 https://t.co/sLQ3MHNcWa
TheDaoIndex KDAO2011 ( View Tweet)
#COVIDvaccine is effective in active and inactive #SLE disease. Noted reduced response for MMF, MTX, GC>10 mg/day. Threshold of B cells is 9+ cell/uL to have a vaccine response. Prof T Dorner #EULAR2022 @rheumnow https://t.co/qyNUZxMccD
TheDaoIndex KDAO2011 ( View Tweet)
RABBIT registry data on CV events with JAKi. Incidence rate low 0.41/100PY. No increase compared to TNFi RR 0.94 (0.39-2.38). No increase in high-risk group RR 0.90 (0.37-2.17). Reassuring with wide CI's. @RheumNow #EULAR2022 OP0135 https://t.co/vBSsnfeBoR https://t.co/iYDZsNwMye
Links:
Richard Conway RichardPAConway ( View Tweet)
Hamroun S et al for the GR2 Cohort showed that age HR 1.22 and use of NSAIDs HR 3.01 in the pre-conception period was associated with a longer time to conception in women with SpA. Research is needed on continuous NSAID use in the preconception period #EULAR2022 @RheumNow OP0153 https://t.co/hl6jUlK5PN
Dr. Antoni Chan synovialjoints ( View Tweet)
#SLE responses with #anifrolimumab separate vs standard of care+placebo& LLDAS at 12 weeks-predictor was high Type I IFN (younger, ⬆️disease activity) but diff sig for response w #belimumab. At bedside diff to tell pts with various signatures apart. #EULAR2022 @RheumNow Dorner https://t.co/98Sb3MIEps
Janet Pope Janetbirdope ( View Tweet)
#OP0143 #EULAR2022 We need to screen/monitor our patients with #lupus for infection. Amsterdam cohort (>200 pts) reported association of infection and flare. 50% were on steroid. Infection type did not influence flare @RheumNow https://t.co/Pxpx5hXLv9
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Dementia in RA associated w/
⚡️Large joint swelling HR 2
⚡️Any CVD HR 2.25
⚡️Anxiety HR 1.86
⚡️Depression HR 2.63
at any time during disease course in retrospective cohort 800+ pts
#EULAR2022 @RheumNow OP0134 @MyasoedovaElena https://t.co/MLweRMEZXE
Aurelie Najm AurelieRheumo ( View Tweet)
#EULAR2022 OP0135:
German RABBIT 🐇 Registry:
⭐️ Observational, 46% Tofa, 54% Bari
No increased rate of CVD in JAK vs TNF inhibitor
🚨Unlike the ORAL Surveillance
@RheumNow https://t.co/O4IXg22Ybc
Eric Dein ericdeinmd ( View Tweet)
How many and quickly does nr-AxSpA progress to r-AxSpA? Poddubnyy et al for the PROOF study showed that 16% of nr-AxSpA pts progressed to r-AxSpA within 5 years, mean time to radiographic progression was 2.4 years #EULAR2022 @RheumNow OP0149 https://t.co/KTC8Xkt4ey
Dr. Antoni Chan synovialjoints ( View Tweet)
Good morning from Copenhagen. Starting the day with looking at imaging in SpA, review of posters, vaccination, lupus nephritis and auto inflammatory disease #EULAR2022 @RheumNow https://t.co/aPEkLjDaK7
Dr. Antoni Chan synovialjoints ( View Tweet)
Another promising drug for #SLE! Monoclonal Ab to BDCA2 ; phase II study noted improvement in joint manifestation but not impressive in cutaneous dz. - Prof T Dorner #EULAR2022 @rheumnow https://t.co/eKwQyomJUD
TheDaoIndex KDAO2011 ( View Tweet)
#ClinicalPearl 2/3 of pts with #SLE have Type 1 interferon signature. So, 1/3 of #lupus is NOT driven by this pathway. Importance may be what is targeted in each pt but doesn’t necessarily predict response to #anifrolimumab #EULAR2022 @eular_org @RheumNow T Dorner SLE session https://t.co/vMOC8yGJ2V
Janet Pope Janetbirdope ( View Tweet)
#EULAR2022 OP0136:
PROTECT-RA Cohort - 150 pts established RA
Cholesterol loading capacity (CLC) on macrophages
⭐️High CLC correlates with CV events
⭐️bDMARD use affects CLC
@RheumNow https://t.co/9ngaH9yUI7
Eric Dein ericdeinmd ( View Tweet)
Mortality after PMR:
looking at 35y follow-up of a cohort in Norway,
apparent higher mortality for women (vs men, general population) decades after.
Is this real? Treatment related?
My wild guess: sarcopenia kills.
Thoughts @Sarah_L_Mackie & tagged?
OP0181 #EULAR2022 @RheumNow https://t.co/k7p9jNfW5s
David Liew drdavidliew ( View Tweet)
#OP0144 #EULAR2022 Promising Digital use in monitoring disease activity for clinicians. Researchers in Amsterdam developed the first e-health #SLE T2T. High acceptance rate re: usability. Need more validation and in different languages @RheumNow https://t.co/7LravXhoJ8
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Sometimes hear “GCA associated with PMR is extracranial”
Interesting point:
of the 20% of PMR patients with USS-evident subclinical GCA
- one-quarter had isolated cranial disease
GCA phenotypes not so clear cut
(Proviso: it’s subclinical disease)
OP0184 #EULAR2022 @RheumNow https://t.co/storHFL8aW
David Liew drdavidliew ( View Tweet)
Farshad et al. 17% of admissions on long-term allopurinol had it held. Reasons - acute gout flare, renal impairment, gastrointestinal issues, cytopenia, drug interactions, NPO status, and always discontinued the medication. @RheumNow #EULAR2022 OP0169 https://t.co/ADOomiOrRi https://t.co/nxAAOMWsJB
Links:
Richard Conway RichardPAConway ( View Tweet)
RABBIT registry and MACE in RA
No difference between
*JAKi (Tofa and Bari) and *TNFi in both unselected and high CV risks patients.
🧨 different than ORAL surveillance
but Observational and overall Low incidence (28 events).
#EULAR2022 @RheumNow OP0135 https://t.co/o8rngHrwQF
Aurelie Najm AurelieRheumo ( View Tweet)